MMP9 and pertussis: We assessed whether the in vitro levels of LTF, PTX-3, and MMP-9 might also predict in vivo vaccine reactogenicity by comparing the fold changes of each protein across two vaccine treatment groups: (1) Alum-adjuvanted HBV (Recombivax) vaccine of low reactogenicity (53) and (2) EasyFive, a combination vaccine containing whole cell pertussis vaccine of high reactogenicity (54).